Table 2. Univariate and multivariate analysis of the vemurafenib subgroup.

	Univariate analysis			Multivariate analysis
Variable	Hazard ratio	95% CI	P	Hazard ratio	95% CI	P
ECOG (0 (n=29) vs >0 (n=38))	1.007	0.505–2.006	0.985	—	—	—
LDH (⩽ 250 (n=26) v.>250 U/l (n=41))	1.514	0.805–2.849	0.199	1.698	0.959–3.008	0.070
Brain metastases (no (n=26) vs yes (n=41))	1.194	0.637–2.24	0.580	—	—	—
Period BRAFi RT (⩽58 days (n=37) vs>58 days (n=30))	1.155	0.668–1.999	0.606	—	—	—
Toxicity (no (n=33) vs any (n=34))	1.656	0.622–4.407	0.312	1.455	0.635–3.334	0.376
Drugs (only BRAFi (n=30) vs drug prior to BRAFi (n=37))	1.746	0.991–3.077	0.054	1.654	0.955–2.866	0.073
Vemurafenib (concomitant (n=36) vs interrupted (n=31))	0.683	0.309–1.512	0.347	0.507	0.293–0.877	0.015

Abbreviations: BRAFi=BRAF inhibitor; CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase.

Variables associated with a P-value <0.35 in univariate analyses were considered for inclusion in multivariate analyses. P-values <0.05 were considered to be statistically significant and were marked in bold.